FDA granted accelerated approval to axicabtagene ciloleucel (Yescarta) for treatment of adults with relapsed or refractory follicular lymphoma

Approval is based on results from the single-arm, open-label ZUMA-5 study (n=146; median follow-up 14.5 months) in which 91% of patients achieved a response and 60% achieved complete remission after two or more lines of failed systemic therapy.

Source:

Biospace Inc.